South Korean RNA-editing firm enters Eli Lilly’s San Diego innovation hub to speed its precision gene-therapy pipeline toward the clinic.
Biotech real estate has its own hierarchy, and San Diego sits near the top. So when a Seongnam-based RNA therapeutics company buys itself a desk inside Eli Lilly’s newest innovation outpost there, it’s worth asking what that access is actually worth and whether it says more about the company or about Lilly’s appetite for outside science.
Rznomics Inc announced that it is joining Lilly Gateway Labs (LGL), the pharma giant’s San Diego hub for biotech companies working alongside its scientists and executives [1]. LGL sits under Lilly Catalyze360, the umbrella that also houses Lilly Ventures, Lilly ExploR&D and Lilly TuneLab – Lilly’s answer to the growing pressure on Big Pharma to source innovation externally rather than build it all in-house.
The arrangement gives Rznomics wet-lab space and, perhaps more valuably, proximity. Sitting inside the same building as Lilly scientists tends to accelerate the unglamorous parts of drug development: informal conversations, faster feedback loops, introductions that don’t show up in a press release but decide whether a molecule gets a second look.
Rznomics says the move will help it accelerate candidate discovery across a target gene database spanning more than 200 disease targets, while it works on establishing clinical infrastructure in the US, expanding partnerships and recruiting R&D talent stateside.
This isn’t Rznomics’ first entanglement with Lilly. The two signed a research collaboration and licensing agreement back in May 2025 focused on a novel RNA-editing therapeutic, so the San Diego move reads less like a first date and more like moving in together. Rznomics listed on South Korea’s KOSDAQ exchange that December, giving it fresh capital and a public profile to match its ambitions.
“Joining Lilly Gateway Labs in San Diego represents a meaningful milestone for Rznomics’ proprietary RNA platform,” said Seong-Wook Lee, CEO of Rznomics. “We intend to advance the development and commercialization of our RNA therapeutics by active collaboration with the global biotech ecosystem.”
Rznomics’ platform is built around trans-splicing ribozymes – engineered RNA molecules that can, in effect, edit a faulty piece of genetic message while it’s still being read by the cell, swapping out the damaged section for a corrected one. It’s a subtler tool than the gene-slicing scissors of CRISPR, and one that its developers argue could reach disease targets other editing approaches struggle to touch cleanly.
Among the company’s earlier-stage programs is a candidate aimed at telomerase activity – the enzyme that governs how much a cell’s chromosome-protecting telomeres wear down with each division – in liver and brain cancers. It’s a cancer program first and foremost, not a longevity therapy.
However, telomerase sits at the center of one of biology’s oldest arguments about aging: cells that can’t manage it well tend to either die off too fast or, in cancer’s case, refuse to die at all. Tools capable of dialing that switch with precision are being watched closely well beyond oncology, including by researchers hunting for ways to slow cellular aging without triggering runaway cell growth.
For a clinical-stage company still building out its Western presence, geography is strategy. San Diego is one of the few places on earth where a biotech can plausibly bump into its next investor, its next hire and its next partner within a five-minute walk. Rznomics is betting that proximity converts into speed, and that speed, in RNA therapeutics, is currency.
Whether the bet pays off will show up less in this announcement than in what Rznomics can show a year from now: pipeline candidates that have moved, partnerships that have widened, and – if the telomerase-linked work advances – a clearer signal of how precision RNA editing might eventually earn a seat at longevity science’s table, not just oncology’s.
